Figure 2.
Principal mechanisms of action of the three naked mAbs (elotuzumab, daratumumab and isatuximab) and the ADC (belantamab mafodotin) approved for the treatment of MM.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.